DK1189620T3 - Formulering indeholdende testosteronundecanoat og amerikansk olie - Google Patents

Formulering indeholdende testosteronundecanoat og amerikansk olie

Info

Publication number
DK1189620T3
DK1189620T3 DK00920588T DK00920588T DK1189620T3 DK 1189620 T3 DK1189620 T3 DK 1189620T3 DK 00920588 T DK00920588 T DK 00920588T DK 00920588 T DK00920588 T DK 00920588T DK 1189620 T3 DK1189620 T3 DK 1189620T3
Authority
DK
Denmark
Prior art keywords
testosterone undecanoate
solution
liquid carrier
formulation containing
american oil
Prior art date
Application number
DK00920588T
Other languages
Danish (da)
English (en)
Inventor
De Henrik Nijs
Susan Chandler
Elizabeth Anne Perry
Josephine Joan Chri Ferdinando
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK1189620T3 publication Critical patent/DK1189620T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK00920588T 1999-04-01 2000-03-27 Formulering indeholdende testosteronundecanoat og amerikansk olie DK1189620T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01

Publications (1)

Publication Number Publication Date
DK1189620T3 true DK1189620T3 (da) 2004-08-16

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00920588T DK1189620T3 (da) 1999-04-01 2000-03-27 Formulering indeholdende testosteronundecanoat og amerikansk olie

Country Status (27)

Country Link
EP (1) EP1189620B1 (pt)
JP (1) JP2002541111A (pt)
KR (1) KR100666016B1 (pt)
CN (1) CN1155385C (pt)
AT (1) ATE269708T1 (pt)
AU (1) AU768537B2 (pt)
BR (1) BR0009465A (pt)
CA (1) CA2366856C (pt)
CZ (1) CZ298573B6 (pt)
DE (1) DE60011771T2 (pt)
DK (1) DK1189620T3 (pt)
ES (1) ES2222199T3 (pt)
HK (1) HK1043544A1 (pt)
HU (1) HU229455B1 (pt)
ID (1) ID30481A (pt)
IL (2) IL145524A0 (pt)
MX (1) MXPA01009919A (pt)
NO (1) NO329420B1 (pt)
NZ (1) NZ514290A (pt)
PL (1) PL195163B1 (pt)
PT (1) PT1189620E (pt)
RU (1) RU2246296C2 (pt)
SK (1) SK286071B6 (pt)
TR (1) TR200102769T2 (pt)
TW (1) TWI280124B (pt)
WO (1) WO2000059512A1 (pt)
ZA (1) ZA200107781B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP2985026B1 (en) * 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
PT2068825E (pt) 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2525520T3 (es) * 2010-04-12 2014-12-26 Clarus Therapeutics, Inc. Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
HUE037660T2 (hu) * 2011-01-26 2018-09-28 Allergan Inc Androgén készítmény szembetegség kezelésére
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CA2950670A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
WO2015193380A2 (en) * 2014-06-19 2015-12-23 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160193225A1 (en) * 2014-08-29 2016-07-07 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
TR200102769T2 (tr) 2002-05-21
NO20014718D0 (no) 2001-09-28
MXPA01009919A (es) 2002-04-24
NO20014718L (no) 2001-09-28
HU229455B1 (en) 2013-12-30
PL195163B1 (pl) 2007-08-31
CZ298573B6 (cs) 2007-11-14
KR20010108435A (ko) 2001-12-07
JP2002541111A (ja) 2002-12-03
ZA200107781B (en) 2002-12-20
BR0009465A (pt) 2002-01-08
DE60011771T2 (de) 2004-11-04
PT1189620E (pt) 2004-10-29
SK13722001A3 (sk) 2002-02-05
IL145524A0 (en) 2002-06-30
WO2000059512A1 (en) 2000-10-12
DE60011771D1 (de) 2004-07-29
EP1189620B1 (en) 2004-06-23
HUP0200453A3 (en) 2003-06-30
HK1043544A1 (en) 2002-09-20
EP1189620A1 (en) 2002-03-27
ID30481A (id) 2001-12-13
SK286071B6 (sk) 2008-02-05
CZ20013507A3 (cs) 2002-03-13
TWI280124B (en) 2007-05-01
ES2222199T3 (es) 2005-02-01
HUP0200453A2 (hu) 2002-07-29
AU768537B2 (en) 2003-12-18
CN1155385C (zh) 2004-06-30
KR100666016B1 (ko) 2007-01-10
RU2246296C2 (ru) 2005-02-20
ATE269708T1 (de) 2004-07-15
IL145524A (en) 2006-12-31
CA2366856A1 (en) 2000-10-12
CN1346274A (zh) 2002-04-24
PL351259A1 (en) 2003-04-07
CA2366856C (en) 2006-05-16
NZ514290A (en) 2003-08-29
AU4111100A (en) 2000-10-23
NO329420B1 (no) 2010-10-18

Similar Documents

Publication Publication Date Title
DK1189620T3 (da) Formulering indeholdende testosteronundecanoat og amerikansk olie
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
CA2185347A1 (en) A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
MXPA04000535A (es) FORMULACIONES ANTIHISTAMINICAS PARA FORMAS DE DOSIFICACION DE CaPSULAS SUAVES.
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
AR023235A1 (es) Formulaciones de androgenos
US20060024341A1 (en) Microemulsion composition and related method
TH33003B (th) สูตรตำรับแอนโดรเจน
TH60756A (th) สูตรตำรับแอนโดรเจน
TH34374B (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
TH40043A (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants